{
    "clinical_study": {
        "@rank": "26688", 
        "acronym": "MicroVIH", 
        "arm_group": [
            {
                "arm_group_label": "Dietary  Supplement: Prebiotics+Glutamine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "A rapid and almost complete loss of CD4+ T cells from the gut associated lymphoid tissue\n      (GALT) occurs early in HIV infection, with a permanent damage in the intestinal barrier,\n      changes in gut microbiota, increased bacterial translocation and persistent immune\n      activation, changes that are not restored after the initiation of antiretroviral therapy.\n      The investigators hypothesize than an intervention targetting the enterocyte barrier and the\n      gut microbiota might modify the gastrointestinal tract towards a bifidogenic microbiota and\n      improve markers of  bacterial translocation, inflammation, immune activation and endothelial\n      dysfunction."
        }, 
        "brief_title": "Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "HIV", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized placebo-controlled clinical trial to evaluate the safety and\n      effectiveness to modify gut microbiota, bacterial translocation, immune activation and\n      markers of endothelial dysfunction of a dietary supplement (prebiotics + glutamine) during a\n      period of six weeks. The study will enroll four cohorts: 1) HIV-infected, treatment naive\n      individuals; 2) HIV-infected subjects, currently on ART, with  >350 CD4+ T-cells/uL; 3)\n      HIV-infected subjects, currently on ART, with <350 CD4+ T-cells/uL; 4) HIV negative healthy\n      controls."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  After receiving information on the design and objectives of the study, the possible\n             risks involved, and the fact that they can refuse to collaborate at any time,\n             patients will give their informed consent to participate in the study and agree to\n             provide material for the cellular and molecular studies.\n\n          -  Aged over 18 years.\n\n          -  Group 1: HIV+, Not receiving ART and no previous exposure to ART, at least 2 years\n             since HIV diagnosis.\n\n          -  Group 2: HIV+, currently receiving ART for more than 2 years, HIV-1 RNA levels less\n             than 40 copies/ml and more than 350 CD4+ T-cells/uL.\n\n          -  Group 3: HIV+, currently receiving ART for more than 2 years, HIV-1 RNA levels less\n             than 40 copies/ml and less than 350 CD4+ T-cells/uL.\n\n          -  Group 4: HIV-, healthy controls.\n\n        Exclusion Criteria:\n\n          -  Major cardiovascular risk factors.\n\n          -  Concomitant acute diseases.\n\n          -  Gastrointestinal disorders.\n\n          -  Pregnancy.\n\n          -  Antibiotic exposure in the previous month.\n\n          -  Regular use of foods or supplements containing prebiotics or probiotics within the 2\n             weeks prior to initiation of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838915", 
            "org_study_id": "11/284"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dietary  Supplement: Prebiotics+Glutamine", 
                "description": "Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.\nGlutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function.", 
                "intervention_name": "Prebiotics+Glutamine", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Maltodextrin, 20 g.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HIV", 
            "immunoactivation", 
            "bacterial translocation", 
            "prebiotics", 
            "glutamine", 
            "microbiota"
        ], 
        "lastchanged_date": "August 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28034"
                }, 
                "name": "Hospital Ram\u00f3n y Cajal and Hospital Cl\u00ednico San Carlos"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Gut Microbiota, Bacterial Translocation, Immune Activation and Endothelial Dysfunction in HIV Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events monitoring during the intervention", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Soluble CD14 and increasing permeability binding protein.", 
                "measure": "Changes in markers of bacterial translocation", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Changes in percentages of CD4+ and CD8+ T-cells expressing CD25, HLADR, CD38.", 
                "measure": "Changes in markers of immunoactivation", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Changes in interleukine-6 and high-sensitivity C Reactive Protein", 
                "measure": "Changes in inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Changes in asymmetric dimethylarginine and flow-mediated dilation", 
                "measure": "Changes in markers of endothelial dysfunction", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Changes in gut microbiota as determined by 454 pyrosequencing.", 
                "measure": "Changes in gut microbiota composition", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838915"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal", 
            "investigator_full_name": "Sergio Serrano-Villar", 
            "investigator_title": "Post-Doctoral Researcher", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in gut microbiota by 454 pyrosequencing of fecal samples.", 
                "measure": "Changes in gut microbiota", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Levels of CD4+ T-cell and HIV-1 RNA copies/mL", 
                "measure": "Disease progression in HIV-infected patients.", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Thymic function", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Gene expression in peripheral blood monocytic cells.", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}